Targeting the HGF/Met signalling pathway in cancer.

[1]  T. Nakagawa,et al.  E7050: A dual c‐Met and VEGFR‐2 tyrosine kinase inhibitor promotes tumor regression and prolongs survival in mouse xenograft models , 2010, Cancer science.

[2]  A. Tolcher,et al.  A phase Ib dose-escalation study of orally administered MP-470, a multi-kinase inhibitor and supressor of Rad51, in combination with carboplatin doublet containing regimens shows activity in highly refractory solid tumor patients. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  M. Prados,et al.  Use of neurovascular imaging in GBM patients (pts) to quantify early physiologic changes after treatment with XL184, an inhibitor of multiple receptor tyrosine kinases: Results from a phase II study. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  P. Jänne,et al.  Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non–Small Cell Lung Cancer , 2009, Clinical Cancer Research.

[5]  M. Shah,et al.  Abstract B210: Shed MET (sMET), VEGFA, and sVEGFR2 are markers of foretinib treatment in metastatic gastric cancer patients , 2009 .

[6]  R. Bukowski,et al.  Abstract A36: Plasma biomarkers predicting outcome in patients with advanced RCC: Results from the sorafenib phase III TARGET trial , 2009 .

[7]  M. Cotreau,et al.  Abstract A100: A phase 1, first in human, study of SCH 900105, an antihepatocyte growth factor (HGF) monoclonal antibody, in subjects with advanced solid tumors , 2009 .

[8]  J. Gyuris,et al.  Abstract C173: Anti‐tumor activity of SCH 900105 (AV299), an anti‐HGF antibody, in non‐small cell lung cancer models , 2009 .

[9]  J. Gyuris,et al.  Abstract C181: Preclinical efficacy and pharmacodynamics of SCH 900105 (AV‐299) an anti‐HGF antibody in an intracranial glioblastoma model , 2009 .

[10]  S. Viswanadha,et al.  Abstract C212: Pharmacological and pharmacokinetc characterization of RP1040, a novel and potent c‐Met tyrosine kinase inhibitor , 2009 .

[11]  J. Li,et al.  Abstract B269: Pharmacodynamic and correlative biomarker analyses in clinical trials of XL184, an oral, potent inhibitor of MET, VEGFR2, and RET , 2009 .

[12]  S. Digumarthy,et al.  Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  M. Ratain,et al.  Clinical activity observed in a phase I dose escalation trial of an oral c-met and ALK inhibitor, PF-02341066. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  S. Giordano.  Rilotumumab, a mAb against human hepatocyte growth factor for the treatment of cancer. , 2009, Current opinion in molecular therapeutics.

[15]  J. Christensen,et al.  Enzymatic characterization of c-Met receptor tyrosine kinase oncogenic mutants and kinetic studies with aminopyridine and triazolopyrazine inhibitors. , 2009, Biochemistry.

[16]  M. Shah,et al.  Assessment of two dosing schedules of GSK1363089 (GSK089), a dual MET/VEGFR2 inhibitor, in metastatic gastric cancer (GC): Interim results of a multicenter phase II study. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  M. Prados,et al.  Correlative tumor molecular profiling and plasma biomarker analysis in a phase II study of XL184 in patients with progressive or recurrent glioblastoma multiforme (GBM). , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  M. Mehran,et al.  Phase I study of MGCD265 administered intermittently to patients with advanced malignancies (Study 265-102). , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  P. LoRusso,et al.  Phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of PF-00337210, a highly selective VEGFR inhibitor. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  M. Prados,et al.  A phase II study of XL184 in patients (pts) with progressive glioblastoma multiforme (GBM) in first or second relapse. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  J. Saldanha,et al.  MP470, a novel receptor tyrosine kinase inhibitor, in combination with Erlotinib inhibits the HER family/PI3K/Akt pathway and tumor growth in prostate cancer , 2009, BMC Cancer.

[22]  C. Bailly,et al.  Abstract #835: First bivalent fully antagonist anti-c-Met antibody targeting the c-Met receptor: I) in vitro mechanism of action , 2009 .

[23]  P. Majumder,et al.  Abstract #1751: MK-8033, a selective c-Met / Ron inhibitor, suppresses tumor cell growth in vitro and in vivo , 2009 .

[24]  R. Salgia,et al.  The MET axis as a therapeutic target. , 2009, Update on cancer therapeutics.

[25]  G. V. Vande Woude,et al.  Novel Therapeutic Inhibitors of the c-Met Signaling Pathway in Cancer , 2009, Clinical Cancer Research.

[26]  J. Fargnoli,et al.  Discovery of N-(4-(2-amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide (BMS-777607), a selective and orally efficacious inhibitor of the Met kinase superfamily. , 2009, Journal of medicinal chemistry.

[27]  B. Berghuis,et al.  A Novel Multipurpose Monoclonal Antibody for Evaluating Human c-Met Expression in Preclinical and Clinical Settings , 2009, Applied immunohistochemistry & molecular morphology : AIMM.

[28]  G. Shapiro,et al.  Phase I study of daily administration of MGCD265 to patients with advanced malignancies (Study 265-101). , 2009, Journal of Clinical Oncology.

[29]  Luca Toschi,et al.  Single-Agent and Combination Therapeutic Strategies to Inhibit Hepatocyte Growth Factor/MET Signaling in Cancer , 2008, Clinical Cancer Research.

[30]  M. Shah,et al.  Preliminary activity of XL880, a dual MET/VEGFR2 inhibitor, in MET amplified poorly differentiated gastric cancer (PDGC): Interim results of a multicenter phase II study , 2008 .

[31]  M. Ratain,et al.  A phase I study of XL184, a RET, VEGFR2, and MET kinase inhibitor, in patients (pts) with advanced malignancies, including pts with medullary thyroid cancer (MTC) , 2008 .

[32]  D. Bergstrom,et al.  First in human phase I study of MK-2461, a small molecule inhibitor of c-Met, for patients with advanced solid tumors , 2008 .

[33]  P. Comoglio,et al.  Silencing the MET oncogene leads to regression of experimental tumors and metastases , 2008, Oncogene.

[34]  N. Hanna,et al.  MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling , 2008 .

[35]  J. M. Sauder,et al.  Selective inhibition of MET protein receptor tyrosine kinase by SGX523 , 2007 .

[36]  S. Burley,et al.  In vitro and in vivo antitumor activities of SGX523, a novel MET inhibitor , 2007 .

[37]  W. Linehan,et al.  A phase II study of the dual MET/VEGFR2 inhibitor XL880 in patients (pts) with papillary renal carcinoma (PRC) , 2007 .

[38]  J. Welsh,et al.  Sensitization of a Glioblastoma Multiforme (GBM) Cell Line by MP470: A Novel c-Met Antagonist , 2007 .

[39]  C. Sweeney,et al.  Interim results from a first-in-human study with AMG102, a fully human monoclonal antibody that neutralizes hepatocyte growth factor (HGF), the ligand to c-Met receptor, in patients (pts) with advanced solid tumors , 2007 .

[40]  S. Srinivas,et al.  A phase II study of the c-Met RTK inhibitor XL880 in patients (pts) with papillary renal-cell carcinoma (PRC) , 2007 .

[41]  M. Ratain,et al.  A phase I dose-escalation study of the safety and pharmacokinetics (PK) of XL184, a VEGFR and MET kinase inhibitor, administered orally to patients (pts) with advanced malignancies , 2007 .

[42]  G. Shapiro,et al.  Phase I experience with c-MET inhibitor XL880 administered orally to patients (pts) with solid tumors , 2007 .

[43]  S. Jeay,et al.  ARQ 197, a highly selective small molecule inhibitor of c-Met, with selective antitumor properties in a broad spectrum of human cancer cells , 2007 .

[44]  W. Sandoval,et al.  Utilizing the activation mechanism of serine proteases to engineer hepatocyte growth factor into a Met antagonist , 2007, Proceedings of the National Academy of Sciences.

[45]  M. Park,et al.  From Tpr-Met to Met, tumorigenesis and tubes , 2007, Oncogene.

[46]  E. Lengyel,et al.  Tyrosine kinase mutations in human cancer. , 2007, Current molecular medicine.

[47]  M. Westphal,et al.  A Novel One-Armed Anti-c-Met Antibody Inhibits Glioblastoma Growth In vivo , 2006, Clinical Cancer Research.

[48]  G. Shapiro,et al.  A phase I study of a novel spectrum selective kinase inhibitor (SSKI), XL880, administered orally in patients (pts) with advanced solid tumors (STs). , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[49]  P. Circosta,et al.  Ab-induced ectodomain shedding mediates hepatocyte growth factor receptor down-regulation and hampers biological activity. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[50]  J. Laterra,et al.  Systemic anti-hepatocyte growth factor monoclonal antibody therapy induces the regression of intracranial glioma xenografts. , 2006, Clinical cancer research : an official journal of the American Association for Cancer Research.

[51]  Gayatry Mohapatra,et al.  Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752 , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[52]  Jilin Sun,et al.  Fully human monoclonal antibodies to hepatocyte growth factor with therapeutic potential against hepatocyte growth factor/c-Met-dependent human tumors. , 2006, Cancer research.

[53]  Youhua Liu,et al.  Renal fibrosis: new insights into the pathogenesis and therapeutics. , 2006, Kidney international.

[54]  Somasekar Seshagiri,et al.  Somatic mutations lead to an oncogenic deletion of met in lung cancer. , 2006, Cancer research.

[55]  M. Mori,et al.  Overexpression of NK2 inhibits liver regeneration after partial hepatectomy in mice. , 2005, World journal of gastroenterology.

[56]  Huan Yang,et al.  The Akt/PKB pathway: molecular target for cancer drug discovery , 2005, Oncogene.

[57]  M. Mohammadi,et al.  A protein canyon in the FGF-FGF receptor dimer selects from an à la carte menu of heparan sulfate motifs. , 2005, Current opinion in structural biology.

[58]  Toshikazu Nakamura,et al.  Mechanisms and significance of bifunctional NK4 in cancer treatment. , 2005, Biochemical and biophysical research communications.

[59]  P. Comoglio,et al.  Cancer therapy: can the challenge be MET? , 2005, Trends in molecular medicine.

[60]  Ravi Salgia,et al.  Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer. , 2005, Cancer research.

[61]  E. Lengyel,et al.  C‐Met overexpression in node‐positive breast cancer identifies patients with poor clinical outcome independent of Her2/neu , 2005, International journal of cancer.

[62]  G. Woude,et al.  A Mouse Model of Activating Met Mutations , 2005, Cell cycle.

[63]  D. Bottaro,et al.  Hereditary papillary renal carcinoma type I. , 2004, Current molecular medicine.

[64]  L. Naldini,et al.  An uncleavable form of pro-scatter factor suppresses tumor growth and dissemination in mice. , 2004, The Journal of clinical investigation.

[65]  E. Gherardi,et al.  The Interactions of Hepatocyte Growth Factor/Scatter Factor and Its NK1 and NK2 Variants with Glycosaminoglycans Using a Modified Gel Mobility Shift Assay , 2004, Journal of Biological Chemistry.

[66]  Carmen Birchmeier,et al.  Met provides essential signals for liver regeneration. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[67]  L. Schmidt,et al.  The Met kinase inhibitor SU11274 exhibits a selective inhibition pattern toward different receptor mutated variants , 2004, Oncogene.

[68]  J. Stamos,et al.  The Sema domain of Met is necessary for receptor dimerization and activation. , 2004, Cancer cell.

[69]  L. Naldini,et al.  Targeting the tumor and its microenvironment by a dual-function decoy Met receptor. , 2004, Cancer cell.

[70]  Ryuichi Morishita,et al.  Therapeutic angiogenesis using hepatocyte growth factor (HGF). , 2004, Current gene therapy.

[71]  S. Thorgeirsson,et al.  Hepatocyte growth factor/c-met signaling pathway is required for efficient liver regeneration and repair. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[72]  J. Christensen,et al.  c-Met: Structure, functions and potential for therapeutic inhibition , 2003, Cancer and Metastasis Reviews.

[73]  W. Birchmeier,et al.  Met, metastasis, motility and more , 2003, Nature Reviews Molecular Cell Biology.

[74]  J. Christensen,et al.  A selective small molecule inhibitor of c-Met kinase inhibits c-Met-dependent phenotypes in vitro and exhibits cytoreductive antitumor activity in vivo. , 2003, Cancer research.

[75]  R. Salgia,et al.  c-MET mutational analysis in small cell lung cancer: novel juxtamembrane domain mutations regulating cytoskeletal functions. , 2003, Cancer research.

[76]  J. Christensen,et al.  A novel small molecule met inhibitor induces apoptosis in cells transformed by the oncogenic TPR-MET tyrosine kinase. , 2003, Cancer research.

[77]  W. Birchmeier,et al.  How to make tubes: signaling by the Met receptor tyrosine kinase. , 2003, Trends in cell biology.

[78]  P. Comoglio,et al.  Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. , 2003, Cancer cell.

[79]  G. V. Vande Woude,et al.  HGF/SF‐met signaling in the control of branching morphogenesis and invasion , 2003, Journal of cellular biochemistry.

[80]  G. Merlino,et al.  Constitutive c-Met signaling through a nonautocrine mechanism promotes metastasis in a transgenic transplantation model. , 2002, Cancer research.

[81]  M. Mori,et al.  Overexpression of hepatocyte growth factor/scatter factor promotes vascularization and granulation tissue formation in vivo , 2001, FEBS letters.

[82]  P. Wingfield,et al.  Dissociation of Heparan Sulfate and Receptor Binding Domains of Hepatocyte Growth Factor Reveals That Heparan Sulfate-c-Met Interaction Facilitates Signaling* , 2001, The Journal of Biological Chemistry.

[83]  L. Schmidt,et al.  Structural basis of oncogenic activation caused by point mutations in the kinase domain of the MET proto‐oncogene: Modeling studies , 2001, Proteins.

[84]  K. Matsumoto,et al.  Hepatocyte growth factor: renotropic role and potential therapeutics for renal diseases. , 2001, Kidney international.

[85]  K. Furge,et al.  Met receptor tyrosine kinase: enhanced signaling through adapter proteins , 2000, Oncogene.

[86]  Jun Yu,et al.  Frequency of TPR‐MET rearrangement in patients with gastric carcinoma and in first‐degree relatives , 2000, Cancer.

[87]  A. Bardelli,et al.  Different point mutations in the met oncogene elicit distinct biological properties , 2000, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[88]  A. Bardelli,et al.  Mutant Met-mediated transformation is ligand-dependent and can be inhibited by HGF antagonists , 1999, Oncogene.

[89]  W. Linehan,et al.  Novel mutations of the MET proto-oncogene in papillary renal carcinomas , 1999, Oncogene.

[90]  A. Bardelli,et al.  Uncoupling signal transducers from oncogenic MET mutants abrogates cell transformation and inhibits invasive growth. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[91]  H. Kleinman,et al.  Differential Effects of Hepatocyte Growth Factor Isoforms on Epithelial and Endothelial Tubulogenesis1 , 2022 .

[92]  W. Birchmeier,et al.  Engineered mutants of HGF/SF with reduced binding to heparan sulphate proteoglycans, decreased clearance and enhanced activity in vivo , 1998, Current Biology.

[93]  L. Pannell,et al.  Functional and biophysical characterization of recombinant human hepatocyte growth factor isoforms produced in Escherichia coli. , 1997, The Biochemical journal.

[94]  P. Wingfield,et al.  Heparin Binding and Oligomerization of Hepatocyte Growth Factor/Scatter Factor Isoforms , 1997, The Journal of Biological Chemistry.

[95]  K. Bauer,et al.  Heparin induces dimerization and confers proliferative activity onto the hepatocyte growth factor antagonists NK1 and NK2 , 1996, The Journal of cell biology.

[96]  R. Schwall,et al.  Sulfated Oligosaccharides Promote Hepatocyte Growth Factor Association and Govern Its Mitogenic Activity (*) , 1995, The Journal of Biological Chemistry.

[97]  M. Sharpe,et al.  Scatter factor/hepatocyte growth factor is essential for liver development , 1995, Nature.

[98]  W. Birchmeier,et al.  The Met receptor tyrosine kinase transduces motility, proliferation, and morphogenic signals of scatter factor/hepatocyte growth factor in epithelial cells , 1993, The Journal of cell biology.

[99]  W. Birchmeier,et al.  A functional domain in the heavy chain of scatter factor/hepatocyte growth factor binds the c-Met receptor and induces cell dissociation but not mitogenesis. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[100]  J. Rubin,et al.  Processing of hepatocyte growth factor to the heterodimeric form is required for biological activity , 1992, FEBS letters.

[101]  K. Miyazawa,et al.  Activation of hepatocyte growth factor by proteolytic conversion of a single chain form to a heterodimer. , 1992, The Journal of biological chemistry.

[102]  P. Godowski,et al.  Structure‐function analysis of hepatocyte growth factor: identification of variants that lack mitogenic activity yet retain high affinity receptor binding. , 1992, The EMBO journal.

[103]  J. Rubin,et al.  Identification of a competitive HGF antagonist encoded by an alternative transcript. , 1991, Science.

[104]  N. Fausto.  Hepatocyte growth factor receptor and the c-met oncogene Bottaro DP, Rubin JS, Faletto DL, Chan AM-L, Kmiecik TE, Vande Woude GF, Aaronson SA. Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product. Science 1991;251:802?804 , 1991 .

[105]  J. Rubin,et al.  Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product. , 1991, Science.